NCT00866918
Clinical Trial Information
Trial Number: NCT00866918 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Study ID:
AAML0631
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00866918-D3 | NCT00866918-D3 This data submission (NCT00866918-D3) contains data from AAML0631 publication 30095694. Data from the primary publication can be found in NCT00866918-D1 and -D2. Patients across these submissions have the same deidentified patient IDs. There is one row for each patient enrolled. The dataset provides the information of eligibility of patient enrollment, ISTH DIC score, Induction death, Coagulopathy adverse event status in Induction, specific Coagulopathy adverse event of interest for the patients on AAML0631 as reported in the manuscript. |
| NCT00866918-D2 | NCT00866918-D2 These data provide specific incidence of adverse events in interest. This dataset is necessary to construct Table 3 (Toxicities Reported in >10% of Patients During a Course of Therapy) on the manuscript. |
| NCT00866918-D1 | NCT00866918-D1 There is one row for each patient enrolled. The dataset provides the information of consort flow of patient enrollment, baseline characteristics, adverse event status in each course, induction response, RQPCR (molecular) remission status, and primary outcome for the patients on AAML0631 as reported in the manuscript. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®